Items tagged with Hepatitis C
Report shows UNITAID’s approach vital to remove market barriers so millions can have equitable access to new treatments for infectious diseases
On 14-15 January 2016 in Vilnius, Lithuania, the European Union Joint Action on HIV and Co-infection Prevention and Harm Reduction (HA-REACT) held its first Partnership Forum to kick off activities. HA-REACT addresses existing gaps in the prevention of HIV and other co-infections, especially tuberculosis and viral hepatitis, among people who inject drugs. This is a three-year project which was launched in late 2015 with core funding from the European Union (EU), and is being implemented by 23 partners in 18 EU Member States. Twelve collaborating partners are contributing additional expertise, among them the European Centre for Disease Prevention and Control and the European Monitoring Centre for Drugs and Drug Addiction.
Groundbreaking pledge of United Nations agencies to end HIV, TB and viral hepatitis epidemics in Europe at high-level meeting on ending TB (post)
For the first time, 14 United Nations agencies have joined forces to end the epidemics of HIV, tuberculosis (TB) and viral hepatitis – Europe’s deadliest communicable diseases. The commitment was demonstrated with the launch of the first-ever United Nations Common Position on Ending HIV, TB and Viral Hepatitis through Intersectoral Collaboration in the WHO European Region.
Civil society reaction to the European Commission Staff Working Document on HIV/AIDS, TB and viral hepatitis (post)
Weak signals of political commitment
Call for expressions of interest: Systematic reviews on hepatitis B and hepatitis C co-infection with TB and MDR/RR-TB and the effects of co-administration of MDR/RR-TB and hepatitis C treatment (post)
The World Health Organization (WHO) Global TB Program has initiated a process to conduct systematic reviews for the collection and assessment of available evidence on the prevalence of viral hepatitis B and C among patients with TB and multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB) and whether the concurrent treatment of drug-resistant TB and hepatitis C is safe and increases the likelihood of treatment success and reduces unfavourable treatment outcomes.
Medicines Patent Pool secures its first licence on promising long-acting technologies for malaria, TB, and hepatitis C (post)
Geneva, 21 September 2021 – The Medicines Patent Pool (MPP) today announced that it has signed a licence agreement with Tandem Nano Ltd (TNL), the University of Liverpool (UoL) start-up focused on the development of its proprietary long-acting nanosystems platform technology. The non-exclusive, worldwide licence covers the patents and expertise of promising long-acting injectable technologies (LAIs) that could be applied in three disease areas with a high prevalence in low- and middle-income countries (LMICs): malaria, tuberculosis (TB), and hepatitis C (HCV). The candidate LAIs, currently developed by the Centre of Excellence for Long-acting Therapeutics (CELT) based at UoL, could provide optimal doses of medicines for malaria chemoprophylaxis, TB prevention, and HCV cure. The research teams are designing medicines to be delivered through a single injection to achieve the desired effect on the pathogens over prolonged periods, suppressing the need for daily oral pills, among many other advantages at the individual and the community levels.
UNITAID approves grants of $160 million (post with simple image)
Breakthrough new medicines for drug-resistant TB to be made available for low- and middle-income countries as part of $160 million of new grants funded by UNITAID.
HIV i-Base/TAG: 2014 Pipeline Report (post with simple image)
Latest annual review on pipeline drugs for adults and children, strategies for cure and prevention for HIV, HCV, TB and vaccine research.
Report: Global State of Harm Reduction 2014 (post with simple image)
The report includes the latest estimates around the response to drug-related HIV, viral hepatitis and tuberculosis.
WHO moves to improve access to lifesaving medicines for hepatitis C, drug-resistant TB and cancers (post with simple image)
New WHO Model List of Essential Medicines published; After about 45 years of scarce innovation for TB medicines, 5 new products are included in the List. Four of these, including bedaquiline and delamanid, target multidrug-resistant TB.
Page 1 of 3 · Total posts: 01 2 Last→